当前位置: X-MOL 学术Biomed. Microdevices › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
A microfluidic platform for dissociating clinical scale tissue samples into single cells
Biomedical Microdevices ( IF 3.0 ) Pub Date : 2021-02-02 , DOI: 10.1007/s10544-021-00544-5
Saif Al-Mofty 1 , Mohamed Elsayed 2 , Hassan Ali 3 , Omnia Ahmed 4 , Ahmad Altayyeb 5 , Ahmed Wahby 4 , Mohamed Abdelgawad 3, 6 , Noha Mousa 7
Affiliation  

The advancement of sample preparation techniques is essential for the field of cell-based therapeutics. To obtain cells suited for clinical applications, the entire process starting from acquiring donor tissue biopsy, all through cell transplantation into the recipient, should occur in an integrated, safe, and efficient system. The current laboratory approach for solid tissue-to-cell isolation is invasive and involves multiple incoherent manual procedures running in an open operator-dependent system. Such an approach provides a chain of events for systematic cell loss that would be unfavorable for rare cell populations such as adult and cancer stem cells. A few lab-on-chip platforms were proposed to process biological tissues, however, they were limited to partial tissue dissociation and required additional processing off-chip. Here, we report the first microfluidic platform that can dissociate native biological tissue into ready-to-use single cells. The platform can merge the successive steps of tissue dissociation, debris filtration, cell sieving, washing, and staining in one streamlined process. Performance of the platform was tested with diverse biological tissues and it could yield viable cells that were ready for on or off-chip cell culture without further processing. Microfluidic tissue dissociation using this platform produced a higher number of viable single cells (an average of 2262 cells/ml per milligram of tissue compared to 1233.25 cells/ml/mg with conventional dissociation).



中文翻译:

用于将临床规模组织样本分离成单个细胞的微流体平台

样品制备技术的进步对于基于细胞的治疗领域至关重要。为了获得适合临床应用的细胞,从获取供体组织活检开始,再到细胞移植到受体体内的整个过程都应该在一个完整、安全、高效的系统中进行。当前用于实体组织到细胞分离的实验室方法是侵入性的,涉及在开放的操作员依赖系统中运行的多个不连贯的手动程序。这种方法为系统性细胞丢失提供了一系列事件,这对稀有细胞群(例如成体干细胞和癌症干细胞)是不利的。提出了一些芯片实验室平台来处理生物组织,但是,它们仅限于部分组织解离,并且需要额外的芯片外处理。这里,我们报告了第一个可以将天然生物组织分离成即用型单细胞的微流体平台。该平台可以将组织解离、碎片过滤、细胞筛分、洗涤和染色等连续步骤合并到一个简化的过程中。该平台的性能通过多种生物组织进行了测试,它可以产生可用于芯片上或芯片外细胞培养的活细胞,无需进一步处理。使用该平台的微流体组织解离产生更多数量的活单细胞(平均每毫克组织 2262 个细胞/毫升,而常规解离为 1233.25 个细胞/毫升/毫克)。在一个简化的过程中进行细胞筛分、洗涤和染色。该平台的性能通过多种生物组织进行了测试,它可以产生可用于芯片上或芯片外细胞培养的活细胞,无需进一步处理。使用该平台的微流体组织解离产生更多数量的活单细胞(平均每毫克组织 2262 个细胞/毫升,而常规解离为 1233.25 个细胞/毫升/毫克)。在一个简化的过程中进行细胞筛分、洗涤和染色。该平台的性能通过多种生物组织进行了测试,它可以产生可用于芯片上或芯片外细胞培养的活细胞,无需进一步处理。使用该平台的微流体组织解离产生更多数量的活单细胞(平均每毫克组织 2262 个细胞/毫升,而常规解离为 1233.25 个细胞/毫升/毫克)。

更新日期:2021-02-02
down
wechat
bug